PSTV (Plus Therapeutics) Short Interest

View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Plus Therapeutics's Short Interest

For the Biotechnology subindustry, Plus Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plus Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Short Interest falls into.

Save Embed

;

Save Embed

;

Plus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

XMP0:Germany

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.plustherapeutics.com

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Executives

Richard J Hawkins	director	950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Greg Petersen	director	3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Howard Clowes	director	217 DWIGHT ROAD, BURLINGAME CA 94010
Marc H Hedrick	officer: President	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Sims Andrew John Hugh Macintyre	officer: Chief Financial Officer	4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Robert P Lenk	director	LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Norman D. Lafrance	officer: CHIEF MEDICAL OFFICER	MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van	director	6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance	10 percent owner	MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote	10 percent owner	CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell	director	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino	officer: Chief Medical Officer	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris	officer: VP and GM of Cell Therapy	3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974